Objectives: To develop and validate a multimodality MRI-based radiomics approach to predicting the posttreatment response of lung cancer brain metastases (LCBM) to gamma knife radiosurgery (GKRS).
Methods: We retrospectively analyzed 213 lesions from 137 patients with LCBM who received GKRS between January 2017 and November 2020. The data were divided into a primary cohort (102 patients with 173 lesions) and an independent validation cohort (35 patients with 40 lesions) according to the time of treatment. Benefit result was defined using pretreatment and 3-month follow-up MRI images based on the Response Assessment in Neuro-Oncology Brain Metastases criteria. Valuable radiomics features were extracted from pretreatment multimodality MRI images using random forests. Prediction performance among the radiomics features of tumor core (RFTC) and radiomics features of peritumoral edema (RFPE) together was evaluated separately. Then, the random forest radiomics score and nomogram were developed through the primary cohort and evaluated through an independent validation cohort. Prediction performance was evaluated by ROC curve, calibration curve, and decision curve.
Results: Gender (p = 0.018), histological subtype (p = 0.009), epidermal growth factor receptor mutation (p = 0.034), and targeted drug treatment (p = 0.021) were significantly associated with posttreatment response. Adding RFPE to RFTC showed improved prediction performance than RFTC alone in primary cohort (AUC = 0.848 versus AUC = 0.750; p < 0.001). Finally, the radiomics nomogram had an AUC of 0.930, a C-index of 0.930 (specificity of 83.1%, sensitivity of 87.3%) in primary cohort, and an AUC of 0.852, a C-index of 0.848 (specificity of 84.2%, sensitivity of 76.2%) in validation cohort.
Conclusions: Multimodality MRI-based radiomics models can predict the posttreatment response of LCBM to GKRS.
Key Points: • Among the selected radiomics features, texture features basically contributed the dominant force in prediction tasks (80%), especially gray-level co-occurrence matrix features (40%). • Adding RFPE to RFTC showed improved prediction performance than RFTC alone in primary cohort (AUC = 0.848 versus AUC = 0.750; p < 0.001). • The multimodality MRI-based radiomics nomogram showed high accuracy for distinguishing the posttreatment response of LCBM to GKRS (AUC = 0.930, in primary cohort; AUC = 0.852, in validation cohort).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00330-021-08368-w | DOI Listing |
Arterioscler Thromb Vasc Biol
January 2025
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston. (B.C.-C., N.A.V.G., N.L.P., L.P.E., V.S.K.S., A.M.O., J.L., G.M., O.H., A.D., S.W.Y., C.A.I., K.C.O.M., S. Kotla, J.-i.A.).
Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression.
View Article and Find Full Text PDFTransl Cancer Res
December 2024
Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Background: Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest cancers globally. Despite gemcitabine being a primary chemotherapeutic agent, many patients with PDAC develop resistance, significantly limiting treatment efficacy. This study aims to screen and validate key genes associated with gemcitabine resistance in advanced PDAC using bioinformatics analysis and clinical sample validation, thereby providing potential noninvasive biomarkers and therapeutic targets for overcoming chemoresistance.
View Article and Find Full Text PDFNat Med
January 2025
Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia. We present a case series of five children with HR-NB refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting. Four of them had previously received allogeneic hematopoietic stem cell transplantation.
View Article and Find Full Text PDFMed J Malaysia
January 2025
Universiti Sains Malaysia, School of Medical Sciences, Department of Internal Medicine, Clinical Haematology Unit, 16150 Kubang Kerian, Kelantan, Malaysia.
Introduction: Hodgkin lymphoma (HL) is a hematopoietic malignancy characterized by the presence of Reed Sternberg cells, with generally favourable outcomes compared to other hematological malignancies. This study aims to determine the socio-demographic, clinical and treatment characteristics, as well as the short-term overall survival (OS) and progression-free survival (PFS) rates, of HL patients treated at Hospital Universiti Sains Malaysia (USM), a tertiary centre in northeast peninsular Malaysia.
Materials And Methods: We conducted a retrospective cohort study of HL patients treated from January 1, 2006, to December 31, 2018, with follow-up until December 31, 2021.
Heliyon
January 2025
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with -mutant colorectal cancer.
Methods: In the interval between completing CRT and pelvic exenteration, patients with resectable mutation-positive, locally advanced primary or current colorectal cancer, received 5-6 doses of TG02/GM-CSF.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!